Activity of spiramycin against Toxoplasma gondii in vitro, in experimental infections and in human infection.
The in-vitro, experimental and clinical activities of spiramycin against Toxoplasma gondii have been reviewed. In mammalian cells infected by T. gondii as in various experimental models, spiramycin definitively exerts an inhibitory antitoxoplasmic effect which, clinically, seems useful for preventing congenital toxoplasma infection during pregnancy or for reducing the inflammation in toxoplasmic chorioretinitis. However, spiramycin does not kill the parasite efficiently, and cannot be recommended for eradicating the most severe forms of toxoplasmosis.
Chang
H R
HR
Department of Microbiology, University of Geneva Medical School, Switzerland.
Pechère
J C
JC
D000818:Animals; D006801:Humans; D007933:Leucomycins / Q000627:therapeutic use*; D051379:Mice; D011817:Rabbits; D012453:Saimiri; D014122:Toxoplasma / Q000187:drug effects*; D014123:Toxoplasmosis / Q000188:drug therapy*; D014124:Toxoplasmosis, Animal / Q000188:drug therapy*
D007933:Leucomycins